Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Rosiglitazone

2

II.a Pulmonary edema, noncardiogenic (NCPE)

2
Last update : 20/01/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Thiazolidinedione associated volume overload and pulmonary hypertension.
Therapeutic advances in cardiovascular disease 2008 Dec;2;435-8 2008 Dec
Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus.
Journal of intensive care medicine 2006;21;47-50 2006
Approach to the management of diabetic patients with heart failure: role of thiazolidinediones.
American heart journal 2004 Oct;148;551-8 2004 Oct
Thiazolidinedione-associated congestive heart failure and pulmonary edema.
Mayo Clinic proceedings 2003 Sep;78;1088-91 2003 Sep
Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability.
Diabetologia 2003 Feb;46;288-90 2003 Feb
Management of rosiglitazone-induced edema: two case reports and a review of the literature.
Diabetes technology & therapeutics 2002;4;505-14 2002

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies